Skip to main content
Erschienen in: World Journal of Surgery 9/2006

01.09.2006

Preoperative Positron Emission Tomography with Fluorine-18-Fluorodeoxyglucose is Predictive of Prognosis in Patients with Hepatocellular Carcinoma after Resection

verfasst von: Etsuro Hatano, MD, PhD, Iwao Ikai, MD, PhD, Tatsuya Higashi, MD, PhD, Satoshi Teramukai, PhD, Tatsuo Torizuka, MD, PhD, Tsuneo Saga, MD, PhD, Hideaki Fujii, MD, PhD, Yasuyuki Shimahara, MD, PhD

Erschienen in: World Journal of Surgery | Ausgabe 9/2006

Einloggen, um Zugang zu erhalten

Abstract

Background:

Hepatocellular carcinomas (HCCs) accumulate fluorine-18 fluorodeoxyglucose (FDG) to various degrees. The standardized uptake values (SUVs) of FDG-positron emission tomography (PET) in high-grade HCCs are significantly higher than those in low-grade HCCs.

Aim:

The aim of this study was to evaluate the possible usefulness of FDG-PET in predicting the prognosis of HCC patients after resection. We analyzed the relationship between the tumor to non-tumor SUV ratios (SUV ratio) and surgical outcome in 31 patients.

Results:

Of the 31 cases of HCC studied, seven (23%) exhibited SUV ratios greater than 2, as the cutoff value. The percentage of patients with poorly differentiated HCC was greater in the higher SUV ratio group (SUV ratio >2) than in the lower SUV ratio group (SUV ratio <2) (57 vs. 32%). The overall survival was significantly longer in the lower SUV ratio group than in the higher SUV ratio group (5-year-survival rate: 63 vs. 29% P = 0.006) (median survival time: 2310 vs.182 days).

Conclusion:

The SUV ratio was related significantly to disease-related death as well as other predictive factors, including the number of tumors, the size, stage, and involvement of vessels, and the involvement of the capsule. Consequently, we conclude that the SUV ratio provides information of prognostic relevance in patients with HCC before surgery.
Literatur
1.
Zurück zum Zitat Imamura H, Matsuyama Y, Miyagawa Y, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999;86(8):1032–1038PubMedCrossRef Imamura H, Matsuyama Y, Miyagawa Y, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999;86(8):1032–1038PubMedCrossRef
2.
Zurück zum Zitat Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101(4):796–802PubMedCrossRef Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101(4):796–802PubMedCrossRef
3.
Zurück zum Zitat Shimada M, Hasegawa H, Gion T, et al. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology 1999;46(28):2469–2475PubMed Shimada M, Hasegawa H, Gion T, et al. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology 1999;46(28):2469–2475PubMed
4.
Zurück zum Zitat Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001;39(5):883–917PubMedCrossRef Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001;39(5):883–917PubMedCrossRef
5.
Zurück zum Zitat Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002;32(1):35–46PubMedCrossRef Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002;32(1):35–46PubMedCrossRef
6.
Zurück zum Zitat Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62(6):816–822PubMedCrossRef Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62(6):816–822PubMedCrossRef
7.
Zurück zum Zitat Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83(5):918–924PubMedCrossRef Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83(5):918–924PubMedCrossRef
8.
Zurück zum Zitat Lyshchik A, Higashi T, Nakamoto Y, et al. Dual-phase (18)F-fluoro-2-deoxy- d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2004;15:15 Lyshchik A, Higashi T, Nakamoto Y, et al. Dual-phase (18)F-fluoro-2-deoxy- d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2004;15:15
9.
Zurück zum Zitat Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36(10):1811–1817PubMed Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36(10):1811–1817PubMed
10.
Zurück zum Zitat Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64(14):860–865PubMedCrossRef Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64(14):860–865PubMedCrossRef
11.
Zurück zum Zitat Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997;38(9):1337–1344PubMed Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997;38(9):1337–1344PubMed
12.
Zurück zum Zitat Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35(12):1965–1969PubMed Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35(12):1965–1969PubMed
13.
Zurück zum Zitat Jeng LB, Changlai SP, Shen YY, et al. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology 2003;50(54):2154–2156PubMed Jeng LB, Changlai SP, Shen YY, et al. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology 2003;50(54):2154–2156PubMed
14.
Zurück zum Zitat Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004;130(5):266–272PubMedCrossRef Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004;130(5):266–272PubMedCrossRef
15.
Zurück zum Zitat Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94(11):3314–3319PubMedCrossRef Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94(11):3314–3319PubMedCrossRef
16.
Zurück zum Zitat Wudel LJ Jr, Delbeke D, Morris D, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69(2):117–124; discussion 124–126PubMed Wudel LJ Jr, Delbeke D, Morris D, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69(2):117–124; discussion 124–126PubMed
17.
Zurück zum Zitat Schroder O, Trojan J, Zeuzem S, et al. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998;37(8):279–285PubMed Schroder O, Trojan J, Zeuzem S, et al. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998;37(8):279–285PubMed
18.
Zurück zum Zitat Liangpunsakul S, Agarwal D, Horlander JC, et al. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. Transplant Proc 2003;35(8):2995–2997PubMedCrossRef Liangpunsakul S, Agarwal D, Horlander JC, et al. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. Transplant Proc 2003;35(8):2995–2997PubMedCrossRef
19.
Zurück zum Zitat Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96(6):1877–1880PubMedCrossRef Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96(6):1877–1880PubMedCrossRef
20.
Zurück zum Zitat Kong YH, Han CJ, Lee SD, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol 2004;10(4):279–287PubMed Kong YH, Han CJ, Lee SD, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol 2004;10(4):279–287PubMed
21.
Zurück zum Zitat Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39(10):961–968PubMedCrossRef Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39(10):961–968PubMedCrossRef
22.
Zurück zum Zitat Del Gaudio M, Grazi GL, Principe A, et al. Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis: a univariate and multivariate analysis. Hepatogastroenterology 2004;51(56):510–514PubMed Del Gaudio M, Grazi GL, Principe A, et al. Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis: a univariate and multivariate analysis. Hepatogastroenterology 2004;51(56):510–514PubMed
23.
Zurück zum Zitat Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001;136(1):25–30PubMedCrossRef Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001;136(1):25–30PubMedCrossRef
Metadaten
Titel
Preoperative Positron Emission Tomography with Fluorine-18-Fluorodeoxyglucose is Predictive of Prognosis in Patients with Hepatocellular Carcinoma after Resection
verfasst von
Etsuro Hatano, MD, PhD
Iwao Ikai, MD, PhD
Tatsuya Higashi, MD, PhD
Satoshi Teramukai, PhD
Tatsuo Torizuka, MD, PhD
Tsuneo Saga, MD, PhD
Hideaki Fujii, MD, PhD
Yasuyuki Shimahara, MD, PhD
Publikationsdatum
01.09.2006
Erschienen in
World Journal of Surgery / Ausgabe 9/2006
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-0791-5

Weitere Artikel der Ausgabe 9/2006

World Journal of Surgery 9/2006 Zur Ausgabe

OriginalPaper

Book Reviews

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.